Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. - Wikidata - awgldk - TriplyDB

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

http://www.wikidata.org/entity/Q44528888

about

Rituximab for rheumatoid arthritis Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Rituximab for Rheumatoid Arthritis.Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis.Influenza and pneumococcal vaccination in patients with rheumatoid arthritis in comparison with age- and sex-matched controls: results of a claims data analysis.The role of B cells in transplantation and immunopathic diseases.Vaccinations in patients with immune-mediated inflammatory diseases 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Vaccinations for rheumatoid arthritis.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studies Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease.Diabetes tolerogenic vaccines targeting antigen-specific inflammation Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA).Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis A literature review on the patients with autoimmune diseases following vaccination against infections.In vitro eradication of citrullinated protein specific B-lymphocytes of rheumatoid arthritis patients by targeted bifunctional nanoparticles.Rituximab-treated patients have a poor response to influenza vaccination Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.Effect of rituximab on human in vivo antibody immune responses.Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.Rituximab for the treatment of rheumatoid arthritis: an update.Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.Emerging biotherapies for Sjögren's syndrome.Are anti-infectious vaccinations safe and effective in patients with autoimmunity?The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis.Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.Emerging drugs to treat juvenile idiopathic arthritis.Safety of biologic therapy in rheumatoid arthritis.Overview of safety of non-biologic and biologic DMARDs.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

P2860

Q24186568-A0941EA2-F9F9-487C-9CAD-3B580D241EF9 Q26748200-804040DC-BAF8-4516-ADBC-5D330D12E463 Q26825440-C5E7A413-B868-4E87-BE47-8DF42ED58E08 Q27691388-392AB4D9-C7A8-497E-A238-1CDFB4A513FC Q28080246-7984993B-8972-4781-A158-88F9B174F1BF Q30420964-6C16E844-F159-4D16-8C22-01EC84A23920 Q31111950-80562040-A275-4A67-AA03-FD0BC6885B4F Q33987668-C6B8FCD0-1ED0-427A-A9D9-D59B6018BB04 Q34117134-1908D13B-E8C7-49AA-A9CE-FBBEC250AAFA Q34390072-620DE980-E50E-4678-846F-A39E212AD5B4 Q34424563-44D43FC1-1F18-44D6-8728-6E193EC8CB80 Q34500921-77E7CD14-0B2D-41E2-9318-CFC722CF46FD Q34570956-CEF1AF6C-3750-44E8-BE49-89582D416567 Q35105760-9E35B571-CBA0-4B9E-A650-DF104FEB235D Q35188551-98D5384F-5452-4BCA-B19A-056DC6E38D25 Q35237511-85EEBC70-D684-4178-A035-CBE623E531A6 Q35350912-45C1AA4A-19AD-4309-BA2A-612028321BF7 Q35633471-962527ED-AB7F-4CE1-A1C7-19BFA0A3C8E9 Q35887037-8A5B640F-493E-40C7-AA9B-2D962342119D Q35954596-51666E48-3A27-4BA6-B99F-5B4B3F2C9E36 Q36031285-A96F66D1-15CE-435C-B921-78407471E80B Q36152477-DCDBA5BD-2834-4552-8009-D6DCCD94FF0B Q36219954-DD2E634B-81E9-4735-9A3A-0420D8A119F3 Q36255747-85615685-087E-48B5-86B7-24D54B5B4339 Q36477500-B82A3FAC-6ABB-4994-9293-279153AF82A9 Q36589247-9C62C56F-14CA-406D-86A7-CEE087CA1EA8 Q36745666-66AE3F39-5532-4F22-9083-60B478C2DE81 Q36761926-99D209EE-2495-4517-A132-67015F256320 Q36860483-F8A4099F-6F52-46F5-9F2F-CB5516E97AFF Q37130018-BDEC5C8A-0809-4BF2-8E31-931FB80148A8 Q37444678-B12E81B3-9A4E-4C60-9CB7-D2F972B1B77A Q37690643-308ADFC7-598E-4ED7-BB6D-23D827151A65 Q37729176-2805EED5-5803-4FB1-B84C-A80DB8F61490 Q37762551-CD32EDE6-6D8F-43EB-8E2E-ED8B1574A138 Q37852715-76D80F33-3844-4F22-BE1D-E2D58624B460 Q37859111-78EDF6EB-F91A-43B7-8184-18782A22468A Q37870209-E9602882-34A1-41E5-91A8-CA07F24D3C76 Q37944433-6FBA1BB4-21C9-4CFD-985A-E62071C6DA8B Q38065768-62C1B707-1399-4436-A7C0-E67A7A5DBCF1 Q38071110-0A0A493F-B23B-4FCD-B353-1B645CEA3565

P2860

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

http://www.wikidata.org/entity/Q44528888

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Immunization responses in rheu ...... m a controlled clinical trial.

@en

Immunization responses in rheu ...... m a controlled clinical trial.

@nl

type

label

Immunization responses in rheu ...... m a controlled clinical trial.

@en

Immunization responses in rheu ...... m a controlled clinical trial.

@nl

prefLabel

Immunization responses in rheu ...... m a controlled clinical trial.

@en

Immunization responses in rheu ...... m a controlled clinical trial.

@nl

P1433

Q44528888-34DACD05-EF9F-4E35-AF58-D108C175C5A5

P1476

Q44528888-7FBF9405-460C-4F12-B773-F4AC0ED3080C

P2093

Q44528888-098D657C-1E5C-4ACC-A608-B98F558B3AFC

Q44528888-18250349-786B-4531-A738-CCA9E274741E

Q44528888-23A93E6F-F493-4A12-8D3E-6C5E9F43EA99

Q44528888-2569411E-6653-4C47-9E48-66713B9850EE

Q44528888-3AE608B2-EC08-48CB-8569-7164EC36D4DB

Q44528888-6116A2DE-6FE1-48ED-95BD-B8B5E6C813EC

Q44528888-6C79C66E-1C52-4B82-8E86-64771A319DF5

Q44528888-9C445E46-21C9-476E-8141-0930F22A1568

Q44528888-B11A84B4-E86C-47F9-AB88-D3DA7231926E

Q44528888-E62FAA6D-B5D2-4E53-8DFE-E1AED9EAA061

P2860

Q44528888-7D4B99C3-CC4E-4792-B5ED-B86684EAC139

Q44528888-AD3F0CC0-5B34-43F2-B2A7-7DDB102C4BD9

Q44528888-C64EDCA8-A340-4E05-8E98-43185A975A7D

P304

Q44528888-E15B16B0-046D-44E5-ACB9-5FCB1808DC5F

P31

Q44528888-1E7D5317-EED5-402A-BEC4-4FDADA3E0390

P356

Q44528888-E7E2D325-54AD-43F4-AFF8-8CA47D79DE58

P433

Q44528888-6B8E4BE6-B40A-450F-A542-5B33D53FA4C9

P478

Q44528888-96525AD9-8430-4B23-B8C7-D2AB7BD28329

P577

Q44528888-D6E5DF53-CF2D-43AA-960A-4D23EC7C5C2A

P5875

Q44528888-792BECA2-1095-4E43-9094-8D66A88EAB74

P698

Q44528888-9C1AB30D-7FC2-4EC5-AA33-0672EEBAE76F

P921

Q44528888-F42EAE50-4E36-48FF-B84C-939ED3583E47

P356

P1433

Arthritis & Rheumatology

P1476

Immunization responses in rheu ...... m a controlled clinical trial.

@en

P2093

Ariella Kelman

http://www.w3.org/2001/XMLSchema#string

Atul Deodhar

http://www.w3.org/2001/XMLSchema#string

Benjamin Trzaskoma

http://www.w3.org/2001/XMLSchema#string

Christine Codding

http://www.w3.org/2001/XMLSchema#string

Clifton O Bingham

http://www.w3.org/2001/XMLSchema#string

Flavius Martin

http://www.w3.org/2001/XMLSchema#string

Maria Greenwald

http://www.w3.org/2001/XMLSchema#string

Neal Halsey

http://www.w3.org/2001/XMLSchema#string

R John Looney

http://www.w3.org/2001/XMLSchema#string

Sunil Agarwal

http://www.w3.org/2001/XMLSchema#string

P2860

Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.

Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.

Specific humoral immunity in the elderly: in vivo and in vitro response to vaccination.

P304

64-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.25034

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40806342

http://www.w3.org/2001/XMLSchema#string

P698

20039397

http://www.w3.org/2001/XMLSchema#string

P921